Dr. Brian Chuck Tse, MD

Dr. Tse practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Tse's NPI, 1629202890, was assigned on May 4, 2009. Dr. Tse graduated from University of Miami, Miller School of Medicine in 2009. Dr. Tse holds Florida license ME119294.

Dr. Tse's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Tse's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Tse to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tse practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Tse's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Tse is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Tse's licenses on file in 2 states: Florida and Tennessee.

Dmand AI lists conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and visual impairment and blindness among the conditions Dr. Tse treats.

CMS data shows 922 Medicare services from Dr. Tse across 14 procedure codes in 2024, for 512 Medicare patients. Medicare paid $85,864 for them.

CMS counts 512 Medicare patients who saw Dr. Tse in 2024. The largest group is 75 to 84, with 219 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tse's median patient age at 73, with 60% women.

In 2024, Dr. Tse wrote 461 Medicare Part D claims for 296 patients. 66% of them were for generic drugs. CMS names the drug for 398 of them, across 4 drugs with 11 or more claims each, at $5,120 in total drug cost. In 2023, CMS named 357 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Tse for performance year 2024, reported as part of a group. Dr. Tse accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tse as offering telehealth. CMS counts 17 procedures of melanoma (skin cancer) excision by Dr. Tse, more than 72% of the clinicians it reports for that procedure.

Dmand AI links 31 papers to Dr. Tse, published from 2012 to 2025. 2022 was the busiest year, with 4. The most frequent topics are Eyelids, Optic Nerve Injuries and Retinal Ganglion Cells. Dr. Tse has published most often in Ophthalmic Plast Reconstr Surg. Dr. Tse's most frequent co-authors are David T. Tse, MD, Kevin Clauss, MD and Marissa Katherine Shoji.

CMS Open Payments shows 36 general payments to Dr. Tse from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Horizon Pharma plc paid the most, $363.

Dmand AI lists 3 awards for Dr. Tse, most recently Marvin H. Quickert Thesis Award in 2018.

Dr. Tse graduated from University of Miami, Miller School of Medicine in 2009. Dr. Tse is a member of AAO, American Society of Ophthalmic Plastic and Reconstructive Surgery, North American Society of Academic Orbital Surgeons and Pan-American Ocular Oncology Society.

Dr. Tse is in network with 15 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.